SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001438533-21-000014
Filing Date
2021-05-06
Accepted
2021-05-06 16:11:11
Documents
16
Period of Report
2021-05-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rtrx-20210506.htm   iXBRL 8-K 41309
2 EX-99.1 a2021q1_ex991.htm EX-99.1 147128
8 image1.jpg GRAPHIC 12958
  Complete submission text file 0001438533-21-000014.txt   370754

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rtrx-20210506.xsd EX-101.SCH 2498
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rtrx-20210506_cal.xml EX-101.CAL 781
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rtrx-20210506_def.xml EX-101.DEF 1737
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rtrx-20210506_lab.xml EX-101.LAB 25298
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rtrx-20210506_pre.xml EX-101.PRE 13261
9 EXTRACTED XBRL INSTANCE DOCUMENT rtrx-20210506_htm.xml XML 11214
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 21897850
SIC: 2834 Pharmaceutical Preparations